Latest data from the FLAIR and CAPTIVATE trials, presented at EHA 2025

Phase III FLAIR trial:

Ibrutinib + venetoclax with MRD-guided duration of treatment vs ibrutinib vs FCR in patients with CLL¹

Population:

N = 786

Adaptive trial design:


FCR was first compared with ibrutinib + rituximab; the trial design was later adapted to include the I and I+V arms


I+V vs FCR primary endpoint: PFS


I+V vs I primary endpoint: MRD negativity **Eligibility:** Previously untreated CLL


Median age: 62 years

STUDY DESIGN (ISRCTN01844152)









Final analysis of fixed-duration ibrutinib + venetoclax in


Phase II CAPTIVATE trial:

patients with CLL/SLL² **Eligibility:** Previously untreated CLL/SLL; aged ≤70 years. **Median age:** 60 years N = 202

Population:

STUDY DESIGN (NCT02910583)

FD I+V arm (n = 159)MRD cohort placebo arm with




Same dose I+V as the FD I+V arm

confirmed uMRD (n = 43)

Patients received 1 additional cycle

of I+V at MRD-guided randomization, then placebo



benefit of the all-oral, once-daily, chemotherapy-free I+V regimen in patients with previously untreated CLL.^{1,2} MRD-guided duration of therapy may further optimize outcomes.¹

EHA, European Hematology Association; EOT, end of treatment; FCR, fludarabine + cyclophosphamide + rituximab; FD, fixedduration; I, ibrutinib; I+V, ibrutinib + venetoclax; mIGHV, mutated IGHV; MRD, measurable residual disease; mTP53, mutated TP53; neg, negativity; NR, not reached; ORR, overall response rate; OS, overall survival; PB, peripheral blood; PFS, progressionfree survival; SLL, small lymphocytic lymphoma; uIGHV, unmutated IGHV; uMRD, undetectable measurable residual disease.

BM, bone marrow; C, cycles; CLL, chronic lymphocytic leukemia; del, deletion; dMRD, detectable measurable residual disease;

References: 1. Munir T. Oral Abstract #S155. EHA 2025 Congress; Jun 12–15, 2025; Milan, IT; 2. Ghia P. Oral Abstract #S156. EHA 2025 Congress; Jun 12–15, 2025; Milan, IT.



